Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vision and hearing during deferoxamine therapy.

A Cohen1, M Martin, J Mizanin

  • 1Division of Hematology, Children's Hospital of Philadelphia, PA 19104.

The Journal of Pediatrics
|August 1, 1990
PubMed
Summary

Deferoxamine chelation therapy rarely causes eye and auditory complications, even at high doses or with moderate iron overload. Most patients remained free of abnormalities, with no progression observed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

tDNA(ser) sequences are involved in the excision of Streptomyces griseus plasmid pSG1.

Gene·1992
Same author

Expression of cytokines and their receptors by human thymocytes and thymic stromal cells.

Immunology·1992
Same author

Conservative surgery and radiation therapy for intraductal carcinoma of the breast.

The Journal of the Florida Medical Association·1992
Same author

Asymmetry in visual search for targets defined by differences in movement speed.

Journal of experimental psychology. Human perception and performance·1992
Same author

Clinical decision making for discharge planning in a changing psychiatric environment.

Health & social work·1992
Same author

Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn.

Cancer research·1992

Area of Science:

  • Pharmacology
  • Ophthalmology
  • Audiology

Background:

  • Deferoxamine is a key iron-chelating agent for transfusional iron overload.
  • Previous reports suggested a high frequency of ocular and auditory toxicity.
  • The relationship between deferoxamine dosage, iron stores, and these complications requires further clarification.

Purpose of the Study:

  • To assess the incidence of eye and auditory complications in patients on deferoxamine.
  • To investigate the correlation between these complications, drug dosage, and serum ferritin levels.

Main Methods:

  • A cohort of 52 regularly transfused patients receiving deferoxamine via subcutaneous or intravenous infusion was studied.
  • Patients had varying iron stores, indicated by serum ferritin levels from 185 to 17,775 µg/L.

Related Experiment Videos

  • Dosages ranged from 26 to 136 mg/kg/day.

    • Main Results:

    • 94% of patients (49/52) showed no drug-induced visual or auditory abnormalities.
    • One patient experienced symptomatic vision and hearing loss, which resolved upon cessation of therapy.
    • Mild, non-progressive ophthalmologic (macular stippling) and audiologic (high-frequency hearing loss) abnormalities were noted in two other patients.

    Conclusions:

    • Eye and ear abnormalities associated with deferoxamine may occur less frequently than previously suggested.
    • Toxicity is not consistently linked to higher drug doses or lower iron stores.
    • Careful monitoring is essential, but complications may not be as uniformly high, even with significant chelation therapy.